Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PK, safety, and tolerability study of TAK-664 (Cuvitru) in IG treatment-naïve primary immunodeficiency
2026-000263-39Phase 4
- Sponsor
- Takeda
- Start
- Aug 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyvalent human immunoglobulin in Immunogenetic disorder, sponsored by Takeda. Primary endpoint: Percentage of participants who achieve a total serum IgG trough level of >=500 mg/dL on Day 15.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2026-000263-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000263-39.